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 Abstract 
 
The TRIPS Agreement and Patent Protection of Pharmaceuticals 
 
The purpose of my thesis is to analyse the global system of pharmaceutical 
patent protection under the TRIPS agreement and to answer the question whether the 
specific character of these products and the need for their general availability is 
adequately addressed at present and, if possible, what are the changes needed in order to 
do so. The thesis is composed of four chapters.  
 
Chapter One describes the philosophical background behind the patent 
protection of pharmaceuticals. It consists of two parts. Part One begins with an outline 
of the classical rational arguments in favour of the existence of patent protection as such. 
In order to describe the basic conflict of interests existing in the pharmaceutical industry, 
Part Two then continues with their application on the issue of patent protection and 
access to medicines.  
 
Chapter Two presents a detailed analysis of the pharmaceutical patent protection 
standard under the TRIPS agreement from the perspective of access to medicines. Thus 
it focuses upon the possibilities that exist for securing greater availability of these 
essential products around the world. The chapter consists of four parts. Part One offers a 
brief history of the TRIPS agreement itself. Part Two continues with an analysis of the 
relevant parts of the general provisions and basic principles of TRIPS. Part Three 
focuses upon the different transitional periods offered by TRIPS. Finally, Part Four 
presents a thorough scrutiny of the specific institutes of medicines’ patent protection, 
such as the unified length of the patent term, patentable subject matter and the rights 
conferred by a patent. Some recent developing country cases are analysed as examples. 
 
Chapter Three illustrates certain additional instruments that can be used in the 
public interest. The chapter consists of two parts. Part One describes the options offered 
by different kinds of exceptions to the rights conferred under art. 30 TRIPS. As a 
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practical example, it uses the broadly accepted Bolar-type exception. Part Two 
continues with the now highly debated issue of compulsory licences under art. 31 
TRIPS. It uses a recent Indian example to examine their use on general basis and then 
focuses on the so far very unsatisfactory use of the “paragraph 6” scheme of 
compulsory licences for export to countries with insufficient local manufacturing 
capacities.  
 
Chapter Four looks at the role that subsequent bilateral and regional trade 
agreements play in the context of the main theme of the thesis. As such, the chapter 
consists of two parts. Part One looks at the issue of TRIPS-plus and their impact upon 
the global standard of patent protection in general. Part Two then shows several specific 
examples of the TRIPS-plus measures in relation to pharmaceuticals. To illustrate, it 
draws from 11 different bilateral agreements – with 9 of these having USA as a party 
and the remaining 2 being recent examples of similar EU activity.  
 
There are two major conclusions drawn in the thesis. First, it can be said with 
certainty that, from today’s point of view, the TRIPS agreement indeed offers a variety 
of options, which can be effectively used to secure greater access to medicines even in 
the developing world. However, the research of their actual use worldwide provides a 
rather gloomy picture. Therefore, as an addition to the primary conclusion, the thesis 
stresses the necessity of effective application.  
 
